1 Answers
Anecortave /ænəˈkɔːrteɪv/ is a novel angiogenesis inhibitor used in the treatment of the exudative form of age-related macular degeneration. Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity. If it is approved, it will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane. No development has been reported since 2010.
4 views
Answered